81 FR 35371 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 106 (June 2, 2016)

Page Range		35371-35372
FR Document		2016-12998

Federal Register, Volume 81 Issue 106 (Thursday, June 2, 2016)

[Federal Register Volume 81, Number 106 (Thursday, June 2, 2016)]
[Notices]
[Pages 35371-35372]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-12998]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA SEP for Medications Development.
    Date: June 22, 2016.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.
    Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, NIH, Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 
20892-9550, (301) 451-3086, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Systems Biology Approaches in HIV/AIDS and Substance 
Use (R01).
    Date: July 7, 2016.
    Time: 8:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-402-6626, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)


[[Page 35372]]


    Dated: May 27, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-12998 Filed 6-1-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 106 / Thursday, June 2, 2016 / Notices 35371

Name of Committee: Center for Scientific Institute of Nursing Research, National Dated: May 26, 2016.
Review Special Emphasis Panel; Member Institutes of Health, One Democracy Plaza, Sylvia L. Neal,
Conflict: Topics in Infectious Diseases. 6701 Democracy Boulevard, Room 710, Program Analyst, Office of Federal Advisory
Date: June 27, 2016 Bethesda, MD 20892, (301) 451–5152, yujing_ Committee Policy.
Time: 2:00 p.m. to 5:00 p.m. liu@nih.gov.
Agenda: To review and evaluate grant [FR Doc. 2016–12893 Filed 6–1–16; 8:45 am]
applications. This notice is being published less than 15 BILLING CODE 4140–01–P
Place: National Institutes of Health, 6701 days prior to the meeting due to the timing
Rockledge Drive, Bethesda, MD 20892, limitations imposed by the review and
(Telephone Conference Call). funding cycle. DEPARTMENT OF HEALTH AND
Contact Person: John C Pugh, Ph.D., (Catalogue of Federal Domestic Assistance HUMAN SERVICES
Scientific Review Officer, Center for Program Nos. 93.361, Nursing Research,
Scientific Review, National Institutes of National Institutes of Health, HHS) National Institutes of Health
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 435– Dated: May 26, 2016. National Institute on Drug Abuse;
2398, pughjohn@csr.nih.gov. Sylvia L. Neal, Notice of Closed Meetings
(Catalogue of Federal Domestic Assistance Program Analyst, Office of Federal Advisory
Program Nos. 93.306, Comparative Medicine; Committee Policy. Pursuant to section 10(d) of the
93.333, Clinical Research, 93.306, 93.333, Federal Advisory Committee Act, as
[FR Doc. 2016–12896 Filed 6–1–16; 8:45 am]
93.337, 93.393–93.396, 93.837–93.844,
amended (5 U.S.C. App), notice is
93.846–93.878, 93.892, 93.893, National BILLING CODE 4140–01–P
Institutes of Health, HHS). hereby given of the following meetings.
Dated: May 27, 2016. The meetings will be closed to the
DEPARTMENT OF HEALTH AND public in accordance with the
Anna Snouffer,
HUMAN SERVICES provisions set forth in sections
Deputy Director, Office of Federal Advisory
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Committee Policy.
National Institutes of Health as amended. The grant applications and
[FR Doc. 2016–12996 Filed 6–1–16; 8:45 am]
the discussions could disclose
BILLING CODE 4140–01–P National Institute of Arthritis and confidential trade secrets or commercial
Musculoskeletal and Skin Diseases; property such as patentable material,
Notice of Closed Meeting and personal information concerning
DEPARTMENT OF HEALTH AND
individuals associated with the grant
HUMAN SERVICES Pursuant to section 10(d) of the applications, the disclosure of which
Federal Advisory Committee Act, as would constitute a clearly unwarranted
National Institutes of Health amended (5 U.S.C. App.), notice is invasion of personal privacy.
National Institute of Nursing Research; hereby given of the following meeting.
Name of Committee: National Institute on
Notice of Closed Meeting The meeting will be closed to the Drug Abuse Special Emphasis Panel; NIDA
public in accordance with the SEP for Medications Development.
Pursuant to section 10(d) of the provisions set forth in sections Date: June 22, 2016.
Federal Advisory Committee Act, as 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Time: 8:00 a.m. to 5:00 p.m.
amended (5 U.S.C. App.), notice is Agenda: To review and evaluate
as amended. The grant applications and
hereby given of the following meeting. cooperative agreement applications.
the discussions could disclose
The meeting will be closed to the Place: Hilton Garden Inn Bethesda, 7301
confidential trade secrets or commercial
public in accordance with the Waverly Street, Bethesda, MD 20814.
property such as patentable material,
provisions set forth in sections Contact Person: Jose F. Ruiz, Ph.D.,
and personal information concerning Scientific Review Officer, Office of
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
individuals associated with the grant Extramural Policy and Review, National
as amended. The grant applications and
applications, the disclosure of which Institute on Drug Abuse, NIH, Room 4228,
the discussions could disclose
would constitute a clearly unwarranted MSC 9550, 6001 Executive Blvd., Bethesda,
confidential trade secrets or commercial
invasion of personal privacy. MD 20892–9550, (301) 451–3086, ruizjf@
property such as patentable material, nida.nih.gov.
and personal information concerning Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial Name of Committee: National Institute on
individuals associated with the grant Drug Abuse Special Emphasis Panel; Systems
applications, the disclosure of which Review Group Arthritis and Musculoskeletal
Biology Approaches in HIV/AIDS and
would constitute a clearly unwarranted and Skin Diseases Clinical Trials Review Substance Use (R01).
invasion of personal privacy. Committee. Date: July 7, 2016.
Date: June 21–22, 2016. Time: 8:30 a.m. to 5:00 p.m.
Name of Committee: National Institute of
Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant
Nursing Research Special Emphasis Panel
Fellowship Training Grants. Agenda: To review and evaluate grant applications.
Date: June 9, 2016. applications. Place: Bethesda North Marriott Hotel &
Time: 11:00 a.m. to 12:00 p.m. Place: Bethesda Marriott Suites, 6711 Conference Center, 5701 Marinelli Road,
Agenda: To review and evaluate grant Democracy Boulevard, Bethesda, MD 20817. Bethesda, MD 20852.
applications. Contact Person: Kathy Salaita, Sc.D., Chief, Contact Person: Gerald L. McLaughlin,
Place: National Institutes of Health, Office Scientific Review Branch, National Institute Ph.D., Scientific Review Officer, Office of
asabaliauskas on DSK3SPTVN1PROD with NOTICES

of Review, Division of Extramural Activities, of Arthritis, Musculoskeletal and Skin Extramural Policy and Review, National
National Institute of Nursing Research, Institute on Drug Abuse, NIH, DHHS, 6001
Diseases, NIH, 6701 Democracy Blvd., Rm.
National Institutes of Health, One Democracy Executive Blvd., Room 4238, MSC 9550,
818, Bethesda, MD. 20892, 301–594–5033, Bethesda, MD 20892–9550, 301–402–6626,
Plaza, 6701 Democracy Boulevard, Suite 703, Kathy.Salaita@nih.gov.
Bethesda, MD 20892, (Telephone Conference gm145a@nih.gov.
Call). (Catalogue of Federal Domestic Assistance (Catalogue of Federal Domestic Assistance
Contact Person: Yujing Liu, Ph.D., MD., Program Nos. 93.846, Arthritis, Program Nos.: 93.279, Drug Abuse and
Chief, Office of Review, Office of Review, Musculoskeletal and Skin Diseases Research, Addiction Research Programs, National
Division of Extramural Activities, National National Institutes of Health, HHS) Institutes of Health, HHS)

VerDate Sep<11>2014 18:30 Jun 01, 2016 Jkt 238001 PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\02JNN1.SGM 02JNN1

35372 Federal Register / Vol. 81, No. 106 / Thursday, June 2, 2016 / Notices

Dated: May 27, 2016. This notice is being published less than 15 Dated: May 26, 2016.
Natasha M. Copeland, days prior to the meeting due to the timing David Clary,
limitations imposed by the review and
Program Analyst, Office of Federal Advisory Program Analyst, Office of Federal Advisory
funding cycle.
Committee Policy. Committee Policy.
Name of Committee: Cardiovascular and
[FR Doc. 2016–12998 Filed 6–1–16; 8:45 am] [FR Doc. 2016–12898 Filed 6–1–16; 8:45 am]
Respiratory Sciences Integrated Review
BILLING CODE 4140–01–P Group; Myocardial Ischemia and Metabolism BILLING CODE 4140–01–P
Study Section.
Date: June 23–24, 2016.
DEPARTMENT OF HEALTH AND Time: 8:00 a.m. to 5:00 p.m. DEPARTMENT OF HEALTH AND
HUMAN SERVICES Agenda: To review and evaluate grant HUMAN SERVICES
applications.
National Institutes of Health Place: Hyatt Regency Bethesda, One National Institutes of Health
Bethesda Metro Center, 7400 Wisconsin
Center for Scientific Review; Notice of Avenue, Bethesda, MD 20814 Government-Owned Inventions;
Closed Meetings Contact Person: Kimm Hamann, Ph.D., Availability for Licensing
Scientific Review Officer, Center for
Pursuant to section 10(d) of the Scientific Review, National Institutes of AGENCY: National Institutes of Health.
Federal Advisory Committee Act, as Health, 6701 Rockledge Drive, Room 4118A, ACTION: Notice.
amended (5 U.S.C. App.), notice is MSC 7814, Bethesda, MD 20892, 301–435–
hereby given of the following meetings. 5575, hamannkj@csr.nih.gov. SUMMARY: The inventions listed below
The meetings will be closed to the Name of Committee: Brain Disorders and are owned by an agency of the U.S.
public in accordance with the Clinical Neuroscience Integrated Review Government and are available for
Group; Developmental Brain Disorders Study licensing in the U.S. in accordance with
provisions set forth in sections
Section. 35 U.S.C. 209 and 37 CFR part 404 to
552b(c)(4) and 552b(c) (6), Title 5 Date: June 23–24, 2016.
U.S.C., as amended. The grant Time: 8:00 a.m. to 5:00 p.m. achieve expeditious commercialization
applications and the discussions could Agenda: To review and evaluate grant of results of federally-funded research
disclose confidential trade secrets or applications. and development.
commercial property such as patentable Place: Melrose Hotel, 2430 Pennsylvania FOR FURTHER INFORMATION CONTACT:
material, and personal information Avenue NW., Washington, DC 20037. Licensing information may be obtained
concerning individuals associated with Contact Person: Pat Manos, Ph.D., by emailing the indicated licensing
Scientific Review Officer, Center for
the grant applications, the disclosure of contact at the National Heart, Lung, and
Scientific Review, National Institutes of
which would constitute a clearly Health, 6701 Rockledge Drive, Room 5200, Blood, Office of Technology Transfer
unwarranted invasion of personal MSC 7846, Bethesda, MD 20892, 301–408– and Development Office of Technology
privacy. 9866, manospa@csr.nih.gov. Transfer, 31 Center Drive Room 4A29,
Name of Committee: Center for Scientific Name of Committee: Oncology 2— MSC2479, Bethesda, MD 20892–2479;
Review Special Emphasis Panel; PAR13–280: Translational Clinical Integrated Review telephone: 301–402–5579. A signed
Program Project: Mechanisms of Membrane Group; Chemo/Dietary Prevention Study Confidential Disclosure Agreement may
Fusion. Section. be required to receive any unpublished
Date: June 14, 2016. Date: June 23–24, 2016. information.
Time: 12:00 p.m. to 4:00 p.m. Time: 8:00 a.m. to 5:00 p.m. SUPPLEMENTARY INFORMATION:
Agenda: To review and evaluate grant Agenda: To review and evaluate grant
applications. applications.
Technology description follows.
Place: National Institutes of Health, 6701 Place: Warwick Seattle Hotel, 401 Lenora Albumin Binding Immunomodulatory
Rockledge Drive, Bethesda, MD 20892, Street, Seattle, WA 98121. Compositions
(Virtual Meeting). Contact Person: Svetlana Kotliarova, Ph.D.,
Contact Person: David R Jollie, Ph.D., Scientific Review Officer, Center for The invention relates to molecules
Scientific Review Officer, Center for Scientific Review, National Institutes of wherein Evan’s Blue dye is chemically
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, conjugated to CpG Oligonucleotides that
Health, 6701 Rockledge Drive, Room 4150, Bethesda, MD 20892, 301–594–7945, elicit anti-tumoral or infection fighting
MSC 7806, Bethesda, MD 20892, (301)-435– kotliars@mail.nih.gov. immunity. Evans Blue, a symmetric azo
1722, jollieda@csr.nih.gov. Name of Committee: Center for Scientific dye, has high binding affinity to
This notice is being published less than 15 Review Special Emphasis Panel; Drug albumin. Albumin binding ability of
days prior to the meeting due to the timing Discovery and Mechanisms of Antimicrobial Evans blue is utilized with CpGs and
limitations imposed by the review and Resistance.
tumor-specific antigens, in order to
funding cycle. Date: June 23, 2016.
Time: 1:00 p.m. to 2:00 p.m. leverage endogenous albumin that
Name of Committee: Brain Disorders and
Agenda: To review and evaluate grant increases the safety and the potency of
Clinical Neuroscience Integrated Review
Group; Clinical Neuroplasticity and applications. molecular vaccines. As such, the
Neurotransmitters Study Section. Place: American Inn of Bethesda, 8130 molecular entities provided here enable
Date: June 16–17, 2016. Wisconsin Avenue, Bethesda, MD 20814. efficient delivery and prolonged
Time: 8:00 a.m. to 5:00 p.m. Contact Person: John C Pugh, Ph.D., retention in lymph nodes and reduce
Agenda: To review and evaluate grant Scientific Review Officer, Center for systemic toxicity of Evans Blue and
applications. Scientific Review, National Institutes of enhanced the therapeutic potency of
asabaliauskas on DSK3SPTVN1PROD with NOTICES

Place: Renaissance Mayflower Hotel, 1127 Health, 6701 Rockledge Drive, Room 1206,
molecular vaccines.
Connecticut Avenue NW., Washington, DC MSC 7808, Bethesda, MD 20892, (301) 435–
20036. 2398, pughjohn@csr.nih.gov. Potential Commercial Applications:
Contact Person: Suzan Nadi, Ph.D., (Catalogue of Federal Domestic Assistance • Cancer therapeutics
Scientific Review Officer, Center for Program Nos. 93.306, Comparative Medicine; • Infectious disease therapeutics
Scientific Review, National Institutes of 93.333, Clinical Research, 93.306, 93.333, • Lymph node specificity
Health, 6701 Rockledge Drive, Room 5217B, 93.337, 93.393–93.396, 93.837–93.844, • Higher stability/Lower toxicity
MSC 7846, Bethesda, MD 20892, 301–435– 93.846-93.878, 93.892, 93.893, National Development Stage:
1259, nadis@csr.nih.gov. Institutes of Health, HHS) • Early stage

VerDate Sep<11>2014 20:01 Jun 01, 2016 Jkt 238001 PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 E:\FR\FM\02JNN1.SGM 02JNN1

Document Created: 2016-06-02 01:23:04
Document Modified: 2016-06-02 01:23:04

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		June 22, 2016.
FR Citation		81 FR 35371

81 FR 35371 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 106 (June 2, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health